



Press Release

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG:LPC IN
--------------	------------	------------------	------------------

Lupin in alliance with Natco

Alliance to commercialize generic equivalent of FOSRENOL® Tablets

April 09, 2009, Mumbai, India: Lupin Ltd. and Natco announced today an alliance to jointly commercialize generic equivalents of Shire plc's FOSRENOL® (lanthanum carbonate) tablets. Shire had filed a lawsuit against Natco for infringement of two patents for FOSRENOL® in response to an ANDA (Abbreviated New Drug Application) filing by Natco seeking US FDA approval to market and sell generic versions of Shire's 500 mg, 750 mg, and 1 g of the FOSRENOL® tablets.

Natco and Lupin believe that they are amongst one of the first-to-files which would likely lead to 180 days exclusivity. FOSRENOL® had sales of USD 108 Million as of December - 2008 (IMS).

Commenting on the development, Mr. Nilesh Gupta, Group President and Executive Director to the Board, Lupin Limited said, "The alliance creates synergies that will enable portfolio expansion and contribute to consolidating our presence in the US markets. Lupin's proven IP management capabilities, marketing reach and expertise coupled with Natco's solid development and manufacturing abilities make for a great combination."

Mr. Rajeev Nannapaneni, Chief Operating Officer, Natco Pharma said, "Our alliance brings together a strong philosophy of working together to maximize opportunities in an increasingly competitive generic business. We are very happy to be associated with Lupin given their intellectual property management competencies and market strengths in the U.S."

About Lupin

Headquartered in Mumbai, India, **Lupin Limited** is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovascular (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Currently positioned amongst the top five pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.

For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US\$ 694 million) and Rs.4,083 million (US\$ 102 million) respectively.

For further information contact:

Shamsher Gorawara
Head - Corporate Communications,
Lupin Limited
shamshergorawara@lupinpharma.com
Mobile: +919820338555

Sonia Mansata
Text 100
sonia.mansata@text100.co.in
Mobile: +91 98 20 1 124 81